ASCO 2016 Annual Meeting

ASCO 2016 Annual Meeting

Utidelone Plus Capecitabine Active in Patients Heavily Pretreated for Metastatic Breast Cancer

The genetically engineered epothilone analog, utidelone, in combination with capecitabine significantly improved progression-free survival and objective response rates in patients with metastatic breast cancer who were heavily pretreated, compared with capecitabine alone, results of a phase 3 trial presented at the 2016 ASCO Annual Meeting have shown.

Study Supports Increased Role for Surgery in Multimodality Therapy for Early Stage SCLC

Surgery for early stage small cell lung cancer (SCLC) is rarely used. However, results from a population-based database has shown surgery with adjuvant chemotherapy with or without radiation for node-negative SCLC was associated with better survival compared with concurrent chemoradiation, according to a presentation at the 2016 ASCO Annual Meeting.

Palbociclib Plus Fulvestrant Provides Significant Benefit in Hormone Receptor-Positive Metastatic Breast Cancer

ESR1 mutations detected in plasma circulating tumor DNA were identified in a high percentage of patients with hormone receptor-positive metastatic breast cancer, confirming an important role in endocrine resistance, according to an analysis of data from the phase 3 PALOMA-3 reported at the 2016 ASCO Annual Meeting.

ESR1 Mutations Predict Worse Outcome in HR-positive Metastatic Breast Cancer Treated with Aromatase Inhibitors

The presence of circulating ESR1 somatic mutations at disease progression in patients with HR-positive metastatic breast cancer treated with first-line AIs represent a strong and independent poor prognostic value for overall survival but no predictive value, a study presented at the 2016 ASCO Annual Meeting has found.

Next post in ASCO 2016 Annual Meeting